An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.

Outcomes of Immune Checkpoint Inhibitor Rechallenge in Advanced Urothelial Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract ...

Inherited Defects of piRNA Biogenesis Cause Transposon De-Repression, Impaired Spermatogenesis, and Human Male Infertility - Beyond the Abstract ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Tanja Van Dijk discussing DAROTAXEL, a randomized, multicenter, phase II ...

The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...

ASCO 2025 overall survival analysis of enzalutamide plus androgen-deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC), ARCHES study.